Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2014, Article ID 297954, 7 pages
http://dx.doi.org/10.1155/2014/297954
Research Article

Annual Decline in Pentraxin 3 Is a Risk of Vascular Access Troubles in Hemodialysis Patients

1Department of Nephrology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
2Comprehensive Human Sciences, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
3Tsukuba University Hospital Hitachi Medical Education and Research Center, Jonan-cho 2-1-1, Hitachi, Ibaraki 317-0077, Japan

Received 18 November 2014; Revised 3 December 2014; Accepted 9 December 2014; Published 22 December 2014

Academic Editor: Jaime Uribarri

Copyright © 2014 Kei Nagai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Pentraxin 3 (PTX3), a multifunctional modulator of the innate immunoinflammatory response, is higher in patients undergoing hemodialysis than healthy control. Our study focused on annual change in PTX3 levels in patients with chronic hemodialysis, because regularly undergoing hemodialysis for many years modifies vascular inflammatory status. To demonstrate whether annual change in PTX3 is associated with vascular events, we measured blood levels of pentraxins (PTX3 and high-sensitivity C-reactive protein (hsCRP)) at baseline and in the next year in 76 hemodialysis patients and observed 20 patients with vascular access troubles during follow-up years. The annual decline in PTX3, but not hsCRP, is a significant risk of the incidence of vascular access trouble that is a critical and specific complication for hemodialysis patients (hazard ratio; 0.732 per +1 ng/mL/year in PTX3, ). This study is the first to focus on the annual change of pentraxins in a hemodialysis cohort.